Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Oncology Research Group
Nowadays in clinical practice patients with previously untreated metastatic breast cancer often receive taxane-based chemotherapy (paclitaxel or docetaxel) in combination with bevacizumab as it has been shown to increase progression-free survival. There is currently minimal information whether bevacizumab should be given as maintenance therapy after discontinuation of chemotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent
Age ≥18 years
Patients with histologically or cytologically confirmed, HER2-negative, metastatic Breast Cancer
No prior first line treatment for metastatic Breast Cancer
Previous hormonotherapy for metastatic Breast Cancer is allowed
One or more measurable lesions (≥1cm in diameter with spiral CT scan or ≥2cm with conventional techniques) according to RECIST criteria
ECOG performance status ≤2
Adequate haematological, renal and hepatic function
Urine protein \<2+ (dipstick)
Life expectancy of ≥12 weeks
You may not be if
Previous first line treatment for metastatic colorectal cancer(progression \>12 months after the end of adjuvant treatment)
Previous radiotherapy to target lesions
Patients with brain metastases and/or cancerous meningitis
Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma
Patients participating in interventional clinical trial
Clareo Health | Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer
